|
|
| | GSK2110183 Basic information |
| Product Name: | GSK2110183 | | Synonyms: | N-[(1S)-2-Amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide;GSK2110183;Afuresertib (GSK2110183);CS-1729;N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide;GSK2110183;GSK 2110183;GSK-2110183;2-Thiophenecarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-;Afuresertib-F free base | | CAS: | 1047634-63-8 | | MF: | C18H16Cl2F2N4OS | | MW: | 445.31 | | EINECS: | | | Product Categories: | | | Mol File: | 1047634-63-8.mol |  |
| | GSK2110183 Chemical Properties |
| Boiling point | 539.7±50.0 °C(Predicted) | | density | 1.54±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 12.92±0.46(Predicted) |
| | GSK2110183 Usage And Synthesis |
| Description | Afuresertib-F is an analogue of Afuresertib with one more flurorine-atom compared to its parent drug Afuresertib. Afuresertib-F is an ATK inhibitor. Afuresertib, also known as GSK-2110183 or GSK-2110183C, is an cancer drug candidate under clinical trial. | | Uses | An ATK inhibitorAfuresertib-F is used in methods of treating myeloproliferative neoplasms using a combination of a MDM2 inhibitor and a therapeutic agent. |
| | GSK2110183 Preparation Products And Raw materials |
|